Navigation Links
Idenix Pharmaceuticals Reports First Quarter Financial Results
Date:4/30/2009

Total operating expenses 17,326 23,844 ------ ------ Loss from operations (13,315) (21,800) Other income (expense), net (49) 939 ---- --- Loss before income taxes (13,364) (20,861) Income tax benefit 438 401 --- --- Net loss $(12,926) $(20,460) ========= ========= Basic and diluted net loss per share: ($0.23) ($0.36) ======= ======= Shares used in calculation of basic and diluted net loss per share: 56,940 56,274 ====== ====== (1) Stock-based compensation expenses included in operating expenses amounted to approximately: Research and development $439 $660 General and administrative 817 880

                     IDENIX PHARMACEUTICALS, INC.

                CONDENSED CONSOLIDATED BALANCE SHEETS

                          (IN THOUSANDS)

                            (UNAUDITED)

                                                      March 31, December 31,
                                                          2009       2008

    ASSETS
    Cash and cash equivalents                           $62,567    $41,509
    Marketable securities                                     -      1,424
    Receivables from related party                          81
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... will be released on Thursday, August 13, 2015, before ... Pfenex management will host a conference call to discuss ... press release outlining the financial results and business update ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company, is pleased to announce that ... injector (RCI-02) have been locked.  Prototypes for industrial ... prepare for an application for CE mark clearance ... in 2016. (Photo: ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ formalized ... specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, and ... PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... (BI) advanced cell culture products, announces the availability of BI’s line of human ... Biological Industries, these stem cell differentiation media offer a complete system for multipotency ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3
... NORCROSS, Ga., Aug. 18 Immucor, Inc. (Nasdaq: ... the blood transfusion industry, today announced that its board of directors ... its current stock repurchase program. , , ... million shares available for repurchase. To date in its first fiscal ...
... NEW YORK, Aug. 18 /PRNewswire-Asia-FirstCall/ ... ("the Company" or "AOBO"), a pharmaceutical,company dedicated to improving ... range of prescription and over the counter ("OTC"),products in ... Jinji,Capsules and Boke Nasal Spray, were awarded the designation ...
... ISELIN, N.J., Aug. 18 SyntheMed, Inc. ... the development and commercialization of anti-adhesion products, announced today ... the reduction of adhesions following cardiac surgery, has received ... Federation for use in all patients who undergo open ...
Cached Biology Technology:Immucor Announces 2 Million Share Increase to Stock Repurchase Program 2American Oriental Bioengineering's 'Jinji Capsules' and 'Boke Nasal Spray' Designated Among 'China's Top Branded Drugs of 2009' 2American Oriental Bioengineering's 'Jinji Capsules' and 'Boke Nasal Spray' Designated Among 'China's Top Branded Drugs of 2009' 3SyntheMed Receives Russian Regulatory Approval for REPEL-CV(TM) 2
(Date:6/24/2015)... Calif. , June 24, 2015  Synaptics ... of human interface solutions, today announced that Sharp ... to provide secure authentication for its latest flagship ... reached more than 200 million shipments of its ... Sharp reinforces Synaptics, strength, scalability and leadership in ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
(Date:6/23/2015)... 2015 Research and ... the "Body-Worn Temperature Sensors Market - Global ... 2014 - 2020" report to their offering. ... the global body-worn temperature sensors market. The global ... the basis of types, care setting, patient demographic, ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... especially if they,ve been sneaking The highly ... breeding behavior, where non-parents contribute to rearing the offspring ... assumed that male subordinates never gained paternity in the ... online journal PLoS ONE , reveals that some ...
... electoral victory or defeat is influenced by his or ... Stanford University studies of the most recent presidential and ... looking at whether candidates, statements on climate change translated ... and of political science at Stanford, who led two ...
... scientists have received National Science Foundation (NSF) funding to ... understand the behavior of entire ecosystems, part of the ... climate and land-use change. Professor William McDowell ... (NREN) and assistant professor Wilfred Wollheim of NREN and ...
Cached Biology News:Stanford researchers examine impact of 'green politics' on recent national elections 2Stanford researchers examine impact of 'green politics' on recent national elections 3UNH researchers receive NSF grant to 'scale up' stream ecology 2UNH researchers receive NSF grant to 'scale up' stream ecology 3
... Antibody to Cytokeratin 5 / 6 ... molecular weight, basic type of cytokeratin expressed ... cell layers of stratified epithelia as well ... mesothelial cells and mesothelioma. Cytokeratin 6 (56 ...
...
Aldolase A (N-15)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Biology Products: